x
Filter:
Filters applied
- Residents' Clinics
- Rapid CommunicationRemove Rapid Communication filter
- LetterRemove Letter filter
- Lin, Cheng-LiRemove Lin, Cheng-Li filter
Publication Date
Please choose a date range between 2018 and 2018.
Residents' Clinics
1 Results
- Letter to the Editor
Association Between Pancreatic Cancer and Dipeptidyl Peptidase-4 Inhibitors Use in a Case-Control Study
Mayo Clinic ProceedingsVol. 93Issue 12p1874–1876Published in issue: December, 2018- Shih-Wei Lai
- Cheng-Li Lin
- Kuan-Fu Liao
Cited in Scopus: 1Dipeptidyl peptidase-4 inhibitor is an incretin-based agent used to treat type 2 diabetes mellitus, which has been available in the Taiwan market since 2009.1 Pancreatic cancer was the eighth leading cause of cancer death in Taiwan in 2017.2 At present, no definite evidence is available on the association between pancreatic cancer and dipeptidyl peptidase-4 inhibitors in Taiwan. To evaluate this issue, a population-based case-control study was conducted using the database of the Taiwan National Health Insurance Program with 23 million citizens living in the independent country of Taiwan.
